Latest News

An ongoing dose expansion phase of the trial is evaluating CRB-701 plus pembrolizumab for first-line OPSCC.

Blood-based T‑cell receptor sequencing reveals immune “fingerprints” in Lynch syndrome, helping track precancers early and paving the way for new cancer surveillance biomarkers.

How young women with lung cancer face stigma, misdiagnosis, and fertility gaps—plus the equity-driven approach reshaping care and trials.

MD Anderson trial uses psilocybin-assisted therapy to help head and neck cancer patients cope with trauma and improve recovery.

During a live event, Sapna Patel, MD, discussed how to sequence second-line therapy for a patient with BRAF-mutant melanoma after immunotherapy and targeted therapy.

The patients with HNSCC had already been treated with immune checkpoint inhibitors and platinum-based chemotherapy.

Puxitatug samrotecan is now being evaluated in the global phase 3 BLUESTAR-Endometrial-01 trial.

Real-world claims data show alectinib beats crizotinib in ALK+ NSCLC survival, urging early use of newer ALK inhibitors.

"These findings support carboplatin-based IC-CCRT as a promising alternative treatment option for LA-NPC," Jian Guan, MD.

FDA reviews chemo-free mosunetuzumab plus polatuzumab for relapsed/refractory LBCL, promising outpatient second-line care and longer PFS.

ASCO 2026 highlights breast cancer care: gene tests help skip chemo, new SERDs and ADCs improve outcomes, ctDNA guides earlier switches.

Updated NCCN guidelines now recommend CSF-based genomic profiling for biopsy-infeasible high-grade gliomas and glioblastomas, expanding liquid biopsy use in CNS cancer.

During a live event, Prerna Mewawalla, MD, and participants discussed selecting therapy for patients with early relapsed/refractory multiple myeloma who are not candidates for CAR T-cell therapy.

Ofirnoflast is a first-in-class oral allosteric modulator of NEK7 that previously received FDA orphan drug designation.

At the European Hematology Association Congress, researchers presented on novel treatments and combinations for newly diagnosed multiple myeloma, relapsed disease, and smoldering myeloma.

A phase 3 trial of givastomig is expected to begin as early as the fourth quarter of 2026.

A retrospective analysis shows strong outcomes with CAR T-cell therapy in real-world patients with multiple myeloma, Doris K. Hansen, MD, explains.

During a live event, Brittany Siontis, MD, discussed treatment strategies for a patient with a progressive abdominal desmoid tumor.

During a live event, Bruna Pellini, MD, and participants discussed frontline treatment selection for patients with ROS1-positive advanced non–small cell lung cancer, including how evolving efficacy and tolerability data are shifting practice toward newer-generation TKIs.

The FDA set a target date of April 14, 2027 to review ozekibart as targeted treatment for chondrosarcoma.

The phase 3 trial showed benefit with talquetamab/daratumumab with or without pomalidomide as early as the second line in myeloma.

Topline data show no overall survival advantage for lurbinectedin monotherapy or combination therapy over investigators' choice in second-line metastatic small cell lung cancer; drug's first-line maintenance approval remains intact.

The FDA concurrently cleared the VENTANA PTEN (SP218) RxDx assay as a companion diagnostic to identify eligible patients.

EPCORE FL-1 data showed a consistent benefit with epcoritamab-based treatment in follicular lymphoma.

The adjuvant approval of the belzutifan combination is supported by the LITESPARK-022 trial.

FBEM conditioning in ALL alloHSCT yields 92.1% 2-year OS and 14.3% relapse rate, with 0% 100-day NRM and manageable GVHD in 203 patients.

Real-world data show tarlatamab achieved 27.7% ORR and manageable toxicity in heavily pretreated patients with ES-SCLC with brain metastases at a single academic center.

In vivo anti-BCMA CAR T infusion shows favorable efficacy and safety with some patients beyond 9 months free of progression.

The supplemental biologics license application is supported by the phase 3 ATOMIC trial.

Alembic receives tentative FDA approval for generic larotrectinib capsules, a TRK inhibitor for NTRK fusion–positive solid tumors, with potential 180-day exclusivity.

FDA granted RMAT designation to lasme-cel, a CD22-targeting allogeneic CAR-T, for R/R B-ALL, the first such therapy in a pivotal trial for this indication.